- The US Food and Drug Administration (FDA) has granted orphan drug status Intellia therapeutics‘ NTLA Lead asset NTLA-2002 for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on daily volume of 901.43 thousand shares, ending the regular trading session at $59.97. The company’s shares traded at $60.96, up 1.65 percent in the after-hours trading session.
- vaxart VXRT announced positive top-line data from the first part of a planned two-part Phase 2 study of its oral COVID-19 vaccine candidate VXA-CoV2-1.1-S in Wuhan S. Vaxart shares were trading up 2.26 percent, ranging from $2.91 to $3.17 on daily volume of 5.23 million shares versus a three-month average volume of 2.57 million shares, ended the regular Trading session at $3.15. The company’s shares traded at $3.10, down 1.59 percent in the after-hours trading session.
- The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) review is scheduled for October 28, 2022 Y mAbs therapeutics‘ YMAB Biological License Application (BLA) for its product candidate OMBLASTYS (omburtamab) for pediatric patients with CNS/leptomeningeal metastases from neuroblastoma. Y-mAbs shares traded in a range of $15.23 to $16.06 on daily volume of 157.04 thousand shares, ending the regular trading session at $16.01.
- Novavax NVAX announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has been approved for Extended Conditional Marketing Authorization (CMA) in the European Union (EU) as a homologous and heterologous active immunization booster for the prevention of COVID-19 caused by SARS- CoV, was recommended. 2 for adults over 18 years old. Novavax shares traded in a range of $30.69 to $32.93 on daily volume of 4.73 million shares and closed the regular trading session at $31.95.
- Pfizer PFE and BioNTech SE BNTX announced a 30mcg booster dose of their bivalent COVID-19 vaccine Omicron BA.1, approved by the…
[ad_2]
Source story
